Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
A short half-life in the circulation limits the application of therapeutics such as single-domain antibodies (VHHs). We utilize red blood cells to prolong the circulatory half-life of VHHs. Here we present VHHs against botulinum neurotoxin A (BoNT/A) on the surface of red blood cells by expressing c...
| Main Authors: | , , , , , , , , |
|---|---|
| Other Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group,
2017-12-12T14:46:21Z.
|
| Subjects: | |
| Online Access: | Get fulltext |